Scalper1 News
InterMune stock vaulted 36% on the stock market today, a day after the biotech company agreed to be bought by Roche for $8.3 billion. The rumor mill had been grinding since Aug. 13, when InterMune (ITMN) hired financial advisers for a possible sale. The price comes to $74 a share, 38% above InterMune’s Friday closing price and 63% above its Aug. 12 closing price. At that time, Bloomberg reported that not only Roche (RHHBY) but Sanofi (SNY), Scalper1 News
Scalper1 News